---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-25-000493"
form_type: "8-K"
ticker: "TEVA"
cik: "0000818686"
company_name: "TEVA PHARMACEUTICAL INDUSTRIES LTD"
filed_at: "2025-01-29T23:59:59+00:00"
generated_at: "2026-05-27T07:42:31.126769+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Teva FY2024 revenue $16.5B, GAAP EPS loss $1.45; non-GAAP EPS $2.49; sees 2025 rev $16.8-17.4B

## Summary
- FY2024 revenues $16.5B, +4% USD (+6% local currency); GAAP net loss $1.639B ($1.45/share) vs $559M loss in FY2023.
- Non-GAAP diluted EPS $2.49, down from $2.56; adjusted EBITDA $4.78B.
- Key product revenues: AUSTEDO >$1.6B, AJOVY $507M (+18% local), UZEDY $117M.
- Generics grew 15% in U.S., 6% in Europe, 15% in International Markets (local currency).
- FY2025 outlook: revenue $16.8-$17.4B, non-GAAP EPS $2.35-$2.65, free cash flow $1.6-$1.9B.

## SEC filing metadata
- accession: 0001171843-25-000493
- form_type: 8-K
- ticker: TEVA
- cik: 0000818686
- company_name: TEVA PHARMACEUTICAL INDUSTRIES LTD
- filed_at: 2025-01-29T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/818686/000117184325000493/0001171843-25-000493-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/818686/000117184325000493/f8k_012925.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-25-000493
- JSON: https://secwatch.observer/filing/0001171843-25-000493.json
- Plain text: https://secwatch.observer/filing/0001171843-25-000493.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.